Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial
Status:
Terminated
Trial end date:
2021-07-02
Target enrollment:
Participant gender:
Summary
A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of
Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the
ORARIALS-01 trial.